Optimization of culture conditions for high-level expression of soluble and active tumor necrosis factor-α in E. coli

Anti-TNF inhibitors exert their therapeutic effect by inhibition of the excessive amounts of TNF-alpha within the body. Recombinant TNF-alpha should be produced in a soluble refolded form to investigate the effectiveness and efficiency of anti-TNF-alpha compounds. In this research, the designed cassette was subcloned in the pET28a expression vector and expressed in E. coli BL21 (DE3). The identity of the protein was confirmed through SDS-PAGE and Western blotting. After optimizing expression conditions, protein purification was performed using native Ni-NTA affinity chromatography. The biological activity of the soluble recombinant TNF-alpha was investigated using MTT assay. Also, the affinity of an anti-TNF-alpha agent, Altebrel, was investigated against the expressed protein through ELISA. Optimization of TNF-alpha expression conditions represented that the highest expression could be achieved at 37 degrees C using 0.5 mM IPTG 6 h post-induction. The recombinant protein represented an inhibitory effect on the L929 murine fibroblast cell line and was successfully detected by Altebrel in ELISA. Binding kinetics were also studied using Cimzia as an anti-TNF-alpha molecule and 7.2 E-13M was calculated as the equilibrium dissociation constant value (K-D). The significant expression level of the recombinant protein in the soluble form, its high purity, and assessment of its biological activity showed that the expressed protein could be used in tests of ELISA and MTT to assess the activity of anti-TNF-alpha agents.